on June 11, 2007
Published online before print June 11, 2007, doi: 10.1161/CIRCULATIONAHA.106.673442
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on November 1, 2006
From Western Infirmary (E.O., M.B.M., J.J.V.M.), Glasgow, Scotland, United Kingdom; Montréal Heart Institute (E.O.), Montréal, Canada; London School of Hygiene and Tropical Medicine (T.C., S.P.), London, United Kingdom; Case Western Reserve University (I.P.), Cleveland, Ohio; Duke University Medical Center (C.B.G.), Durham, NC; Karolinska Hospital (J.O.), Stockholm, Sweden; AstraZeneca LP (E.L.M.), Wilmington, Del; Brigham & Women’s Hospital (S.D.S., M.A.P.), Boston, Mass; HGM-McMaster Clinic (S.Y.), Hamilton, Ontario, Canada; and Sahlgrenska University Hospital/Östra (K.S.), Göteborg, Sweden. * To whom correspondence should be addressed. E-mail: j.mcmurray{at}bio.gla.ac.uk.
Background--We wished to test previous hypotheses that sex-related differences in mortality and morbidity may be due to differences in the cause of heart failure or in left ventricular ejection fraction (LVEF) by comparing fatal and nonfatal outcomes in women and men with heart failure and a broad spectrum of left ventricular ejection fraction. Methods and Results--We compared outcomes in 2400 women and 5199 men randomized in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program using multivariable regression analyses. A total of 1188 women (50%) had a low LVEF ( Conclusions--Among patients with heart failure, women have lower risks of most fatal and nonfatal outcomes that are not explained, as previously suggested, by LVEF or origin of the heart failure.
Accepted on April 8, 2007
Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program
Eileen O’Meara MD,
0.40), and 1212 had a preserved LVEF (>0.40). Among the men, 3388 (65%) had a low LVEF, and 1811 had a preserved LVEF. A total of 1216 women (51%) and 3465 men (67%) had an ischemic cause of their heart failure. All-cause mortality was 21.5% in women and 25.3% in men (adjusted hazard ratio [HR], 0.77; 95% CI, 0.69 to 0.86; P<0.001). Fewer women (30.4%) than men (33.3%) experienced cardiovascular death or heart failure hospitalization (adjusted HR, 0.83; 95% CI, 0.76 to 0.91; P<0.001). The risks of sudden death (HR, 0.70; 95% CI, 0.58 to 0.85) and death due to worsening heart failure (HR, 0.72; 95% CI, 0.58 to 0.89) were reduced to a comparable extent. The adjusted risk of cardiovascular hospitalization was also lower in women (HR, 0.88; 95% CI, 0.82 to 0.95), mainly because of a reduced risk of heart failure hospitalization (HR, 0.87; 95% CI, 0.78 to 0.97). Women had a lower risk of death irrespective of cause of heart failure or LVEF.
Key words: heart failure • sex • etiology • mortality
This article has been cited by other articles:
 |
|
 |
|
  B. B. Granger, I. Ekman, C. B. Granger, J. Ostergren, B. Olofsson, E. Michelson, J. J.V. McMurray, S. Yusuf, M. A. Pfeffer, and K. Swedberg Adherence to medication according to sex and age in the CHARM programme Eur J Heart Fail, November 1, 2009; 11(11): 1092 - 1098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Hsich and I. L. Pina Heart failure in women: a need for prospective data. J. Am. Coll. Cardiol., August 4, 2009; 54(6): 491 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J S Floras Should sleep apnoea be a specific target of therapy in chronic heart failure? Heart, July 1, 2009; 95(13): 1041 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Meier and C. S. Duvernoy Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study Eur J Heart Fail, June 1, 2009; 11(6): 631 - 631. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kalogeropoulos, V. Georgiopoulou, S. B. Kritchevsky, B. M. Psaty, N. L. Smith, A. B. Newman, N. Rodondi, S. Satterfield, D. C. Bauer, K. Bibbins-Domingo, et al. Epidemiology of Incident Heart Failure in a Contemporary Elderly Cohort: The Health, Aging, and Body Composition Study Arch Intern Med, April 13, 2009; 169(7): 708 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shafazand, M. Schaufelberger, G. Lappas, K. Swedberg, and A. Rosengren Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry Eur. Heart J., March 2, 2009; 30(6): 671 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Baumhakel, U. Muller, and M. Bohm Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study Eur J Heart Fail, March 1, 2009; 11(3): 299 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Fermin, A. Barac, S. Lee, S. P. Polster, S. Hannenhalli, T. L. Bergemann, S. Grindle, D. B. Dyke, F. Pagani, L. W. Miller, et al. Sex and Age Dimorphism of Myocardial Gene Expression in Nonischemic Human Heart Failure Circ Cardiovasc Genet, December 1, 2008; 1(2): 117 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schou, C. Torp-Pedersen, F. Gustafsson, J. Abdulla, and L. Kober Wall motion index, estimated glomerular filtration rate and mortality risk in patients with heart failure or myocardial infarction: A pooled analysis of 18,010 patients Eur J Heart Fail, July 1, 2008; 10(7): 682 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gonzalez, M. Rota, D. Nurzynska, Y. Misao, J. Tillmanns, C. Ojaimi, M. E. Padin-Iruegas, P. Muller, G. Esposito, C. Bearzi, et al. Activation of Cardiac Progenitor Cells Reverses the Failing Heart Senescent Phenotype and Prolongs Lifespan Circ. Res., March 14, 2008; 102(5): 597 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Law ARBs Outperform ACE Inhibitors in Women With Heart Failure DOC News, November 1, 2007; 4(11): 10 - 10. [Full Text]
|
|